- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Long-Term Follow-Up Supports Use of Hypofractionated Radiotherapy in Early-Stage Breast Cancer
December 7th 2012, 5:33pm
San Antonio Breast Cancer Symposium
Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.
Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care
December 7th 2012, 3:57pm
San Antonio Breast Cancer Symposium
Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
Dr. Yarnold on Hypofractionation in the START Trials
December 7th 2012, 3:33pm
San Antonio Breast Cancer Symposium
John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.
Adjuvant Bevacizumab Falls Short in Triple-Negative Breast Cancer
December 7th 2012, 2:47pm
San Antonio Breast Cancer Symposium
Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.
Dr. Leyland-Jones Discusses the Phase III HERA Trial
December 7th 2012, 12:50pm
San Antonio Breast Cancer Symposium
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
Study Shows Eribulin Not Superior to Capecitabine in Previously Treated Metastatic Breast Cancer
December 7th 2012, 12:25pm
San Antonio Breast Cancer Symposium
Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.
Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer
December 6th 2012, 4:37pm
San Antonio Breast Cancer Symposium
Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.
Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin
December 6th 2012, 2:19pm
San Antonio Breast Cancer Symposium
Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.
Dr. Aebi on Adjuvant Chemo in Recurrent Breast Cancer
December 6th 2012, 2:14pm
San Antonio Breast Cancer Symposium
Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.
HDAC Inhibition Appears to Sensitize Triple-Negative Breast Cancer Cells to Certain Treatments
December 6th 2012, 2:02pm
San Antonio Breast Cancer Symposium
Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.
Adjuvant Chemotherapy Improves Survival in Women With Recurrent Breast Cancer
December 6th 2012, 11:21am
San Antonio Breast Cancer Symposium
Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.
Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer
December 5th 2012, 4:25pm
San Antonio Breast Cancer Symposium
Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.
New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer
December 5th 2012, 3:44pm
San Antonio Breast Cancer Symposium
Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.
Sentinel Lymph Node Surgery After Chemotherapy Shows Accuracy in Nodal Staging in Breast Cancer
December 5th 2012, 3:36pm
San Antonio Breast Cancer Symposium
Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.
Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer
December 5th 2012, 3:09pm
San Antonio Breast Cancer Symposium
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
Dr. Boughey on Reducing False Negatives in SLN Surgery
December 5th 2012, 2:21pm
San Antonio Breast Cancer Symposium
Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.
Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer
December 5th 2012, 9:35am
San Antonio Breast Cancer Symposium
Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.
Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer
November 2nd 2012, 10:52am
After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.
Dr. Rotkowitz Describes Challenges Facing Immunotherapy
November 2nd 2012, 8:29am
Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.
Meeting Addresses Challenges Facing Urology Groups in Cancer Care
November 1st 2012, 4:55pm
The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.